MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry.

Godino, Cosmo; Munafò, Andrea; Scotti, Andrea; Estévez-Loureiro, Rodrigo; Portolés Hernández, Antonio; Arzamendi, Dabit; Fernández Peregrina, Estefanía; Taramasso, Maurizio; Fam, Neil P; Ho, Edwin C; Asgar, Anita; Vitrella, Giancarlo; Raineri, Claudia; Adamo, Marianna; Fiorina, Claudia; Montalto, Claudio; Fraccaro, Chiara; Giannini, Cristina; Fiorelli, Francesca; Popolo Rubbio, Antonio; ... (2020). MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of heart and lung transplantation, 39(12), pp. 1353-1362. Elsevier 10.1016/j.healun.2020.09.005

Text MitraClip in secondary mitral regurgitation as a bridge to heart transplantation.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (938kB)

BACKGROUND

Patients awaiting heart transplantation (HTx) often need bridging therapies to reduce worsening and progression of underlying disease. Limited data are available regarding the use of the MitraClip procedure in secondary mitral regurgitation for this clinical condition.

METHODS

We evaluated an international, multicenter (17 centers) registry including 119 patients (median age: 58 years) with moderate-to-severe or severe secondary mitral regurgitation and advanced heart failure (HF) (median left ventricular ejection fraction: 26%) treated with MitraClip as a bridge strategy according to 1 of the following criteria: (1) patients active on HTx list (in list group) (n = 31); (2) patients suitable for HTx but awaiting clinical decision (bridge to decision group) (n = 54); or (3) patients not yet suitable for HTx because of potentially reversible relative contraindications (bridge to candidacy group) (n = 34).

RESULTS

Procedural success was achieved in 87.5% of cases, and 30-day survival was 100%. At 1 year, Kaplan-Meier estimates of freedom from the composite primary end-point (death, urgent HTx or left ventricular assist device implantation, first rehospitalization for HF) was 64%. At the time of last available follow-up (median: 532 days), 15% of patients underwent elective transplant, 15.5% remained or could be included in the HTx waiting list, and 23.5% had no more indication to HTx because of clinical improvement.

CONCLUSIONS

MitraClip procedure as a bridge strategy to HTx in patients with advanced HF with significant mitral regurgitation was safe, and two thirds of patients remained free from adverse events at 1 year. These findings should be considered exploratory and hypothesis-generating to guide further study for percutaneous intervention in high-risk patients with advanced HF.

Interest & Impact

Downloads

1 since deposited on 04 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item